Literature DB >> 1171723

External beam radiation therapy of primary carcinoma of the prostate.

M A Bagshaw, G R Ray, D A Pistenma, R A Castellino, E M Meares.   

Abstract

During the past 10 years, some 15 publications have appeared in the English literature on the definitive radiotherapy of prostatic cancer. The long-term followup required for rational assessment of the treatment of prostatic cancer is not yet available for most of these studies. However, in the Stanford series, the direct disease-free survival at 5 years for patients with disease localized to the prostate is 70%; at 10 years, 42%. The direct disease-free survival at 5 years for patients with extracapsular extension in 36%, and at 10 years, 29%. Recently, mapping of potential lymph node metastases has been studies by several authors.Early results of extended-field irradiation required for regional treatment are presented.

Entities:  

Mesh:

Year:  1975        PMID: 1171723     DOI: 10.1002/1097-0142(197508)36:2+<723::aid-cncr2820360817>3.0.co;2-y

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

Review 1.  A history of prostate cancer treatment.

Authors:  Samuel R Denmeade; John T Isaacs
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

2.  Lymph node metastasis in "apparently" localized prostate cancer.

Authors:  R A Castellino; G Ray
Journal:  West J Med       Date:  1976-05

3.  Prostatic cancer.

Authors:  A Rostom
Journal:  Br Med J       Date:  1976-10-16

4.  External radiation therapy of localized prostatic cancer.

Authors:  E K Reddy; S Giri; C M Mansfield
Journal:  J Natl Med Assoc       Date:  1984-01       Impact factor: 1.798

5.  I-125 implant of the prostate: a new technique.

Authors:  P P Kumar; F F Bartone
Journal:  J Natl Med Assoc       Date:  1981-02       Impact factor: 1.798

Review 6.  Radiation therapy approaches to the treatment of high-risk prostate cancer.

Authors:  Soroush Rais-Bahrami; Manish A Vira; Louis Potters
Journal:  Curr Urol Rep       Date:  2009-05       Impact factor: 3.092

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.